Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases

Respirology

Volumn 17, Issue 4, 2012, Pages 693-698

  Fujiwara, Atsushi ^a   Kobayashi, Hiroyasu ^a   Masuya, Masahiro ^a   Maruyama, Mitsuko ^a   Nakamura, Shiho ^a   Ibata, Hidenori ^c   Fujimoto, Hajime ^c   Ohnishi, Masahiro ^a   Urawa, Masahito ^a   Naito, Masahiro ^a   Takagi, Takehiro ^a   Kobayashi, Tetsu ^a   Gabazza, Esteban C ^b   Takei, Yoshiyuki ^a   Taguchi, Osamu ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c National Hospital Organization Mie Chuo Medical Center   (Japan)

Author keywords

biological marker; chemokine; fibrocyte; interstitial lung disease; lung fibrosis

Indexed keywords

CD45 ANTIGEN; COLLAGEN TYPE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MALE; PRIORITY JOURNAL; VASCULAR DISEASE;

ANTIGENS, CD45; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHEMOKINE CXCL12; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; LUNG DISEASES, INTERSTITIAL; MESENCHYMAL STEM CELLS; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 84859900208     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02167.x     Document Type: Article

References (27)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646-64.
2. King TE Jr, Pardo A, Selman M,. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-61.
3. Gabbiani G,. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 2003; 200: 500-3. (Pubitemid 36818250)
4. Phan SH,. Biology of fibroblasts and myofibroblasts. Proc. Am. Thorac. Soc. 2008; 5: 334-7. (Pubitemid 351520680)
5. Lama VN, Phan SH,. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc. Am. Thorac. Soc. 2006; 3: 373-6. (Pubitemid 43845415)
6. Bucala R, Spiegel LA, Chesney J, et al,. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994; 1: 71-81.
7. Abe R, Donnelly SC, Peng T, et al,. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 2001; 166: 7556-62. (Pubitemid 32525636)
8. Herzog EL, Bucala R,. Fibrocytes in health and disease. Exp. Hematol. 2010; 38: 548-56.
9. Strieter RM, Keeley EC, Hughes MA, et al,. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol. 2009; 86: 1111-18.
10. Hartlapp I, Abe R, Saeed RW, et al,. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 2001; 15: 2215-24. (Pubitemid 32927939)
11. Keeley EC, Mehrad B, Strieter RM,. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int. J. Biochem. Cell Biol. 2010; 42: 535-42.
12. Hashimoto N, Jin H, Liu T, et al,. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 2004; 113: 243-52. (Pubitemid 38544209)
13. LaPar DJ, Burdick MD, Emaminia A, et al,. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann. Thorac. Surg. 2011; 92: 470-7.
14. Mehrad B, Burdick MD, Zisman DA, et al,. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem. Biophys. Res. Commun. 2007; 353: 104-8. (Pubitemid 44958347)
15. Moeller A, Gilpin SE, Ask K, et al,. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588-94.
16. Maharaj SS, Baroke E, Gauldie J, et al,. Fibrocytes in chronic lung disease-facts and controversies. Pulm. Pharmacol. Ther. 2011; doi:org/10.1016/j.pupt.2011.09.002
17. Mathai SK, Gulati M, Peng X, et al,. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 2010; 90: 812-23.
18. Tourkina E, Bonner M, Oates J, et al,. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4: 15.
19. Moore BB, Murray L, Das A, et al,. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2006; 35: 175-81. (Pubitemid 44175316)
20. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214: 199-210. (Pubitemid 351160157)
21. Scotton CJ, Chambers RC,. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132: 1311-21. (Pubitemid 47621009)
22. Phillips RJ, Burdick MD, Hong K, et al,. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004; 114: 438-46. (Pubitemid 39071616)
23. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al,. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008; 40: 2129-40.
24. Kohno N, Kyoizumi S, Awaya Y, et al,. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73. (Pubitemid 19176416)
25. van den Blink B, Wijsenbeek MS, Hoogsteden HC,. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2010; 23: 515-20.
26. Yokoyama A, Kohno N, Hamada H, et al,. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1680-4.
27. King TE Jr, Schwarz MI, Brown K, et al,. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. 2001; 164: 1025-32. (Pubitemid 32971653)